Japanese Patient and Physician Preferences for Systemic Therapy Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma: A Discrete Choice Experiment

JRCT ID: jRCT1030220517

Registered date:19/12/2022

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: Hepatocellular carcinoma
• Date of first enrollment: 19/12/2022
• Target sample size: 210
• Study type: Observational

Outcome(s)

Primary Outcome

-Preference weight (strength) given to each attribute with its 95% confidence interval (CI) for patients and physicians.
-Relative importance of the levels of each attribute.

• Secondary Outcome: Treatment preference weight relative to patients' and physicians' characteristics for each attribute and 95% CI.

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

[Patients]
1.Japanese patient aged 18 years or older at the time of informed consent
2.Has HCC history and has undergone TACE within 5 years from the time of informed consent
3.Can understand written Japanese
4.Has undergone systemic therapy (for qualitative survey only)
[Physicians]
1.Hepatologist with a Japanese medical license and enough experience treating HCC in Japan (i.e., average 5 patients / year in the last 3 years)
2.Can understand written Japanese

Exclude criteria

[Patients]
Patient or family member residing with the patient works in pharmaceutical, medical, or market research industries

[Physicians]
None

Related Information

• Primary Sponsor: Kitagawa Hiroshi